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COST-UTILITY OF COCHLEAR IMPLANTS A SOCIETAL
PERSPECTIVE ANALYSIS
Barlev A, Hay JW
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: To perform a cost-utility (Cost per QALY) analy-
sis of cochlear implants from a societal perspective. METHODS:
Model parameters were based upon literature review of Medline
citations. Costs included direct and lifetime maintenance costs,
costs of special education and caregiver support costs. Medical
costs were inﬂated to year 2003 using the medical component of
the CPI. All cost and outcomes were converted to year 2003
values using a base case annual discount rate of 3%. Cost of
treating bacterial meningitis and its complications was included
in the model following a recent FDA warning. The Health Utility
Index Mark III was used to measure utility changes. The ﬁrst
two years post implantation are not included in the utility cal-
culations, reﬂecting patient efforts in adapting to the device.
RESULTS: Including savings on special education, support 
and caregivers time for a child at age 5 who receives cochlear
implants there is a net societal savings of $73,000 over a child’s
lifetime. Lifetime utility gains for a child age ﬁve or less were
0.39 and for all other ages 0.22. For a child age 5 the lifetime
QALYs gained using a 3% discount is 11.47. One way sensitiv-
ity analyses were performed on model parameters. Ranges were
selected based on the high and low values from the studies
included in the analysis. Based on sensitivity analysis the results
remain very favorable with the range of savings to society for
the base case of $44,000–$102,000. CONCLUSION: Cochlear
implant is a dominant strategy from the societal perspective. The
beneﬁt is maximized when the procedure is done before age 5.
Unfortunately, not everyone with hearing loss can beneﬁt from
the procedure and it is difﬁcult to adapt to and maintain the
device.
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OBJECTIVES: Otorrhea is a common complication of acute
otitis media in patients with tympanostomy tubes. The goal 
of this research was to determine the cost-effectiveness of
ciproﬂoxacin 0.3%/dexamethasone 0.1% (CD) combination otic
suspension relative to oﬂoxacin 0.3% otic solution (OFX) for
the treatment of otorrhea. METHODS: A decision-analytic
model emulated the ototopical treatment of otorrhea in patients
with tympanostomy tubes. The economic outcome was the cost
per otorrhea free day (OFD) achieved per episode of care. A clin-
ical algorithm was developed which used three tiers of antimi-
crobial otorrhea therapy. Each successive tier of the model
represented the re-treatment of clinical failures from the preced-
ing tier. First tier therapy compared CD & OFX and used
outcome measures taken from a randomized clinical trial (n =
599). Second tier therapy modeled the use of amoxicillin and
clavulanic acid (ACA) with the outcome measures taken from
the medical literature. Third tier therapy was modeled as being
pathogen speciﬁc and could follow one of three separate path-
ways: 1) intramuscular ceftriaxone; 2) oral ﬂuconazole; and 3)
hospitalization and administration of intravenous antibiotics.
Third tier outcomes were based on expert opinion. All patients
were considered cured upon completion of the clinical algorithm.
Cost information was taken from reference sources and pre-
sented from a payer perspective. The model timeline was 31
days. RESULTS: The estimated cost of otorrhea therapy was
$237.70 for the CD pathway and $255.60 for the OFX pathway.
The estimated number of OFDs per episode of care was 25.4 for
the CD pathway and 23.0 for the OFX pathway. The cost-
effectiveness ratios for CD and OFX therapies were $9 and $11
respectively. CONCLUSIONS: CD was both more effective and
less costly than OFX for the treatment of otorrhea in patients
with tympanostomy tubes. Therefore, CD was the dominant
treatment between the two ototopical alternatives.
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OBJECTIVE: To assess the patient-reported use of caregiving,
assistive devices and services among individuals with age-related
macular degeneration (AMD) and evaluate the impact of visual
impairment level on this use. METHODS: A new instrument, the
AMD Health and Impact Questionnaire, was developed and
pilot-tested for face validity and comprehensiveness. Following
revisions, the survey was published on the Macular Degenera-
tion Partnership’s website. The study was approved by a central
IRB and respondents provided consent before completing the
survey. Responses were analyzed by category of visual impair-
ment as determined by scores from the Visual Function Ques-
tionnaire near and distance scales (none/mild ≥ 68, moderate =
43.6 to 67, severe £43.5). De-identiﬁed data were analyzed in
SAS. RESULTS: Of 443 respondents, 39% were male and the
mean age was 65 years. Respondents with mild visual impair-
ment comprised 42% of the population, moderate and severe
groups comprised 31% and 27%, respectively. Three-fourths of
the population had AMD in both eyes. Use of paid and unpaid
help was signiﬁcantly associated with severity; 10%, 20%, and
71% of the mild, moderate, and severe respondents reported
caregiver assistance (p < 0.0001). Less than 11% of the respon-
dents used assistive services (e.g., counseling, rehabilitation), but
use was signiﬁcantly higher as severity increased (p < 0.05). For
example, less than 6% of respondents with mild impairment but
almost 77% of the most impaired respondents used counseling
services. Use of devices (cane, magniﬁers, computer software)
also increased with severity (mean of 1.3, 2.1, and 3.8 devices
used, p < 0.0001). Using standard costs for devices and services
and a national average for caregiver time, annual costs for mild,
moderate, and severe respondents were $1902, $3553, and
$20,570, respectively. CONCLUSION: There are substantial dif-
ferences in service and device use with increased AMD severity.
Delaying progression of AMD could result in considerable cost
savings.
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Glaucoma is a chronic ophthalmic disease and untreated leads
to progressive loss of vision. OBJECTIVES: The purpose of this
